DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Loxitane (Loxapine Succinate) - Published Studies

 
 



Loxitane Related Published Studies

Well-designed clinical trials related to Loxitane (Loxapine)

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. [2012]

Off-label medication use. [2012]

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. [2011.10]

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. [2011.01]

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. [2011]

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. [2011]

Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. [2010.02]

Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. [1993.06]

The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. [1993.04]

Well-designed clinical trials possibly related to Loxitane (Loxapine)

"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. [2011.08]

"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. [2011]

Amoxapine as an antipsychotic: comparative study versus haloperidol. [2007.12]

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]

Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. [2005.12]

Response of psychotic depression subtypes to pharmacotherapy. [1993.06]

Amoxapine versus amitriptyline for continuation therapy of depression. [1990.10]

Effects of amoxapine and imipramine on evoked potentials in the Continuous Performance Test in patients with affective disorder. [1988]

Other research related to Loxitane (Loxapine)

In vitro aerosol characterization of Staccato((R)) Loxapine. [2011.01.17]

In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine. [2010.08]

Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation. [2010]

Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. [2010]

Loxapine for schizophrenia. [2007.10.17]

Effect of loxapine on electrical brain activity, intracranial pressure, and middle cerebral artery flow velocity in traumatic brain-injured patients. [2007]

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. [2003.01]

Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. [2003]

Loxapine intoxication: case report and literature review. [2000.10]

Loxapine for schizophrenia. [2000]

Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? [1999]

Does loxapine have "atypical" properties? Clinical evidence. [1999]

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. [1997.11]

Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. [1996.12]

The D2 receptor occupancy profile of loxapine determined using PET. [1996.12]

A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. [1996.01]

Mixed fluoxetine/loxapine overdose and atrial flutter. [1994.03]

Neuroleptic malignant syndrome secondary to loxapine. [1991.10]

Other possibly related research studies

Amoxapine-associated acute respiratory distress. [2008.01]

Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature. [2007.12]

HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure. [2007.09.01]

Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. [2007.01]

Simultaneous analysis of classical neuroleptics, atypical antipsychotics and their metabolites in human plasma. [2007.05]

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. [2007.02.27]

Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. [2007.04]

A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs. [2007.03]

Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. [2006.12]

[Therapeutics approach of adult patients with acute and chronic psychotic states: REALITE survey] [2006.07]

Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. [2006.11]

[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review] [2006.07.15]

[Clinical and socio-demographic profile of patients with schizophrenia according to the antipsychotic treatment prescribed] [2006.05]

Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up. [2006.06]

Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. [2005.02]

Treatment of acute mania--from clinical trials to recommendations for clinical practice. [2005.01]

An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. [2004.03.24]

[Case of prolonged recovery from serotonin syndrome caused by paroxetine] [2003]

Photo-distributed neutrophilic drug eruption and adult respiratory distress syndrome associated with antidepressant therapy. [2004.02]

[Survey of management methods for patients in a state of agitation at admission and emergency departments in France] [2003.03]

Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography. Application to management of acute intoxications. [2003.10.05]

Neuroleptic malignant syndrome: case report and discussion. [2003.09.02]

JL 13, an atypical antipsychotic: a preclinical review. [2003.03]

Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. [2003.02]

Discriminative stimulus properties in rats of the novel antipsychotic quetiapine. [2002.11]

Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. [2003.01.01]

Depressive disorders preceding temporal lobe epilepsy. [2002.04]

Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. [2002.04]

[Unexpected drug-interaction] [2002.02]

[Self-poisoning with Datura stramonium. 3 case reports] [2002.01.19]

Meta-analytical studies on new antidepressants. [2001]

Thioridazine for dementia. [2001]

[Body weight changes and psychotropic drug treatment: neuroleptics] [2001.05]

Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. [2001.07]

[A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent] [2000.04]

Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. [2000.06]

Thioridazine for dementia. [2000]

A case of neuroleptic malignant syndrome in a patient with hemodialysis. [2000.02]

Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. [1999]

The role of metabolites in a bioequivalence study II: amoxapine, 7-hydroxyamoxapine, and 8-hydroxyamoxapine. [1999.09]

[Successful treatment using high-dose amoxapine for a depressive patient] [1999.07]

A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. [1999.09]

Repeated propofol anesthesia for a patient with a history of neuroleptic malignant syndrome. [1999.08]

Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. [1999.08.12]

The role of typical and atypical antipsychotic medications in the management of agitation and aggression. [1999]

Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. [1999]

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. [1999]

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. [1999]

Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. [1999.05.01]

[A case of allergic cross reaction between tricyclic antidepressants and maprotiline] [1998.08]

The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. [1998.08]

Changes in regional brain activity in major depression after successful treatment with antidepressant drugs. [1998.07]

Neuroleptic-induced dysphagia. [1997.09]

[Acute poisoning by new psychotropic drugs] [1997.04.01]

The efficacy of antidepressants in post-stroke depression. [1997.03]

A case of drug eruption due to simultaneous sensitization with three different kinds of drugs. [1996.12]

In vitro-in vivo myotoxicity of intramuscular liposomal formulations. [1996.09]

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. [1996.07]

Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. [1996.07]

Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. [1996.05]

ECT in genetically confirmed Huntington's disease. [1996.03]

Treatment of the elderly suffering from psychosis and dementia. [1996]

Amoxapine overdose in a young man: a transient mitochondrial abnormality? [1995.07]

Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. [1995.06]

Successful treatment of amoxapine-induced refractory status epilepticus with propofol (diprivan) [1995.02]

Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. [1994.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017